InsiderClue
Stocks · Health care · Services-Medical Laboratories

Caris Life Sciences, Inc.

CAI Clue Score63
United States Fiscal year ends December CIK 0002019410
$29.70 +8.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $29.70 −4.99% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 18 Jun 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue306.1Operating income−319.6Net income−341.4EPS, diluted−13.24Fiscal year 2024Revenue412.3 +34.7%Operating income−257.1Net income−281.9EPS, diluted−10.66Fiscal year 2025Revenue812.0 +97.0%Operating income45.1Net income−68.1EPS, diluted−3.22
FY2023FY2024FY2025
Revenue 306.1 412.3 812.0
Growth +34.7% +97.0%
Operating income −319.6 −257.1 45.1
Net income −341.4 −281.9 −68.1
Growth
EPS, diluted −13.24 −10.66 −3.22

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin−104.4%Net margin−111.5%Free cash flow margin−97.5%Fiscal year 2024Operating margin−62.4%Net margin−68.4%Free cash flow margin−61.5%Fiscal year 2025Operating margin5.6%Net margin−8.4%Free cash flow margin8.2%
FY2023FY2024FY2025
Operating margin −104.4% −62.4% 5.6%
Net margin −111.5% −68.4% −8.4%
Free cash flow margin −97.5% −61.5% 8.2%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−276.1Capital expenditure−22.3Free cash flow−298.4Buybacks0.0Fiscal year 2024Operating cash flow−245.2Capital expenditure−8.4Free cash flow−253.6Buybacks0.0Fiscal year 2025Operating cash flow83.2Capital expenditure−16.3Free cash flow66.9Buybacks−0.1
FY2023FY2024FY2025
Operating cash flow −276.1 −245.2 83.2
Capital expenditure −22.3 −8.4 −16.3
Free cash flow −298.4 −253.6 66.9
Growth
Buybacks 0.0 0.0 −0.1

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2023Shareholders’ equity−2,145.0Fiscal year 2024Cash64.0Total debt379.5Net cash (debt)−315.6Shareholders’ equity−2,498.8Fiscal year 2025Cash796.3Total debt379.0Net cash (debt)417.3Shareholders’ equity577.3Debt to equity0.66
FY2023FY2024FY2025
Cash n/a 64.0 796.3
Total debt n/a 379.5 379.0
Net cash (debt) n/a −315.6 417.3
Shareholders’ equity −2,145.0 −2,498.8 577.3
Debt to equity n/a n/a 0.66

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
306.1 412.3 812.0
Growth +34.7% +97.0%
116.9 113.9 101.6
149.1 169.4 225.0
−319.6 −257.1 45.1
Growth
−341.4 −281.9 −68.1
0.0 0.0 0.0
−341.4 −281.9 −68.1
Growth
Per share
−13.24 −10.66 −3.22
−13.24 −10.66 −3.22
Growth
34.9 35.5 167.2
34.9 35.5 167.2
Growth +1.6% +371.0%

† The diluted share count jumps at 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 3 of 3 years on file.